Accumulating data on the risk of such disorders suggest that it may extend to indications other than Parkinson’s disease, for example restless legs syndrome and other endocrine disorders.
The active substances associated with impulse control disorders that are available as licensed products in the UK include levodopa, the dopamine agonists apomorphine, bromocriptine, cabergoline, pergolide, pramipexole, quinagolide, ropinirole and rotigotine and the COMT inhibitors benserazide, carbidopa, entacapone and tolcapone.
Monitor regularly for symptoms
The product literature has been updated to warn healthcare professionals to regularly monitor for impulse control disorders and to inform patients of the possibility of such effects. If symptoms develop, dose reduction or discontinuation should be considered.